Reid, There are at least two issues raised. But let's tackle a couple of the important issues.
Big pharma, like all dominant industries, complicates both development and production process to raise the stakes so that none but them can sustain the costs of playing the game. Whereupon their principal concern is for market share -- where investment is greatest. Of course they don't want to refute or renounce the products they've developed! The complex solutions of these products usually tread a very narrow margin between safety and toxicity [you've no doubt read many of the contra-indications associated with these 'solutions']. We do not presume to have developed a Panacea; rather I believe we have reached a [pharmaceutical value/quality] threshold from which much research, far more capable than which we can apply, is needed. We are now engaged in a new [nanotechnology] territory where materials begin to act differently than the micro-range that has only in recent decades begun to be understood. But scientific knowledge has not yet progressed to an understanding of this. In truth, the CS that ...."people can buy [CS] inexpensively".... does not approach either the quality or any standard for a pharmaceutical grade formulation. Having researched some 46 products to date, I can assure you that we have seen such a variety amongst them that it is impossible to suggest that a standard could be deveoped from them. It is true that all 'silvers' work.... to some extent or other. But if you were to apply a standard from 1 to 10 in the range of [bactericidal] efficacy, you'd see everything from 1 to 10 amongst these samples, with a mean average of between 3 and 4, and probably closer to 3. Mind you, most of these products are bactericidal and most more so than such other bactericides that are commonly available as over-the-counter products. That is certainly a mitigating factor in their defense. There is also a serious question relative to the integrity of labeled specifications [ie. concentration(ppm)] amongst these products. They usually vary between 50% and 150%. From such inconsistencies one can only draw the conclusion that most of these manufacturers have no real handle on the material and are only responding to a demand that has been created mostly from anecdotal reports and marketing hyperbole. Such as this is the disservice I have spoken of.... There are too many issues that must be taken into account in processing CS to go into here and now. But much information has become available through such a medium as this 'silver list'. It is a shame that some of the discourse has -- which may have unfortunately descended into confrontation -- been suppressed in defense of 'list ettiquette' or that the list has been deprived of any participant [which it also has been] in such defense. I have personally been enlightened by such discourse, and am appreciative of what I've learned here. I would also like to state here in this context that our motives are primarily driven by the knowledge that CS is one of the most important materials to have evolved from the wisdom of the past. And I firmly believe that it is consistent with true knowledge by which present problems -- some quite critical -- can only be solved in the future. Of course I am also responsible for a commercial enterprise and the considerations that arise from it must also be taken into account. But that is not abnormal nor does it interfere with the scientific enquiry we continue to pursue, and value above all. Stephen > -----Original Message----- > From: Reid Harvey [mailto:[email protected]] > Sent: Tuesday, September 18, 2001 12:07 AM > To: silver digest > Subject: CS>re: new member > > > Stephen, > As you have said, "The much too little legitimate research into CS is > due to 'scientific' and 'official' scepticism. And this is due to the > lack of consistent [even minimal] quality of commercial products that > have opportunistically capitalized on the small body of legitimate > research that does exist...." This last bit doesn't sound > right to me. > Haven't others here been consistently saying that the folks > who make the > drugs have too much invested in the conventional anti biotics to see > something like CS succeed? As simplistic as it may sound, these > companies would be throwing away $Billions annually because people can > buy CS inexpensively. Why do you blame this on current > producers? Surely > this problem goes back to 1938 and before. > Reid > > > -- > The silver-list is a moderated forum for discussion of > colloidal silver. > > To join or quit silver-list or silver-digest send an e-mail > message to: > [email protected] -or- [email protected] > with the word subscribe or unsubscribe in the SUBJECT line. > > To post, address your message to: [email protected] > Silver-list archive: > http://escribe.com/health/thesilverlist/index.html > List maintainer: Mike Devour <[email protected]> > >

